Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.60 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.60 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 2/20 | 0.58 |
| ▸ | VCP | P55072 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12760734 | 1.00 | NFE2L2 (1.00) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL9785833 | 0.91 | NFE2L2 (0.83) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL9785831 | 0.91 | NFE2L2 (0.83) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL1405381 | 0.89 | NFE2L2 (0.81) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL1405379 | 0.89 | NFE2L2 (0.81) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL11301074 | 0.87 | CYP19A1 (0.93) | NFE2L2CYP19A1MAPTFBP1VCP | |
| SCHEMBL11301072 | 0.87 | CYP19A1 (0.93) | NFE2L2CYP19A1MAPTFBP1VCP | |
| SCHEMBL1405454 | 0.85 | PTGS2 (0.75) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL1405456 | 0.85 | PTGS2 (0.75) | NFE2L2CYP19A1PTGS2PTGS1RELA | |
| SCHEMBL1005734 | 0.84 | PTGS2 (0.78) | NFE2L2CYP19A1PTGS2PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| EP-2694061-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | Société Splicos (FR) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | NFE2L2 1922/4885CYP19A1 2298/4885PTGS2 4367/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | NFE2L2 1922/4885CYP19A1 2298/4885PTGS2 4367/4885 |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, CBR3, TP53BP1 | NFE2L2 2308/4885CYP19A1 2173/4885PTGS2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.